natgillin/translations-raw huggingface dataset:
In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients ≤75 years. 
Poleg tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih ≤ 75 let.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
DATE OF REVISION OF THE TEXT <DD month YYYY> 
DATUM ZADNJE REVIZIJE BESEDILA <{DD. mesec LLLL}>
For the HDPE bottle presentation chemical and physical in-use stability have been demonstrated for: 
Kemična in fizikalna stabilnost zdravila v HDPE steklenički je bila dokazana za naslednje obdobje:
• You have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days 
• Če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh.
Patients should inform physicians and dentists that they are taking clopidogrel before any surgery is scheduled and before any new medicinal product is taken. 
Bolniki morajo zdravnike in zobozdravnike obvestiti, da jemljejo klopidogrel, preden določijo termin za kakršenkoli kirurški poseg in preden začnejo jemati katerokoli novo zdravilo.
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (seesection 5.1). 
Podatki iz kliničnih preskušanj podpirajo uporabo do 12 mesecev, največjo korist pa so opazili po 3 mesecih (glejte poglavje 5.1).
Put the tablet in your mouth and swallow with water or another liquid. 
Tableto položitev v usta in jo pogoltnite skupaj z vodo ali drugo tekočino.
• You have had an allergy or reaction to any medicine used to treat your disease. 
• Če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali.
Each tablet contains 62.16 mg lactose monohydrate and 10 mg hydrogenated castor oil. 
Ena tableta vsebuje 62,16 mg laktoze monohidrata in 10 mg hidrogeniranega ricinusovega olja.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs. 
Vendar pa je zaradi pomanjkanja študij o interakcijah z drugimi nesteroidnimi protivnetnimi zdravili trenutno nejasno, ali povečano tveganje za pojav gastrointestinalne krvavitve obstaja pri vseh nesteroidnih protivnetnih zdravilih.
TEVA Santé SA Rue Bellocier 89107 Sens France 
TEVA Santé SA Rue Bellocier 89107 Sens Francija
Pregnancy and breast-feeding It is preferable not to use this medicine during pregnancy. 
Nosečnost in dojenje Priporočljivo je, da tega zdravila v nosečnosti ne uporabljate.
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment. 
Krvavitve so bile najpogosteje opisan učinek tako v kliničnih študijah kot v obdobju trženja zdravila, kjer so se najpogosteje pojavile prvi mesec zdravljenja.
If you cut or injure yourself, it may take slightly longer than usual for bleeding to stop. 
Če se urežete ali poškodujete, lahko traja nekoliko dlje kot običajno, da se krvavitev ustavi.
• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na klopidogrel ali katerokoli sestavino tega zdravila (navedno v poglavju 6).
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular). 
Klopidogrel podaljša čas krvavitve in ga je potrebno uporabljati previdno pri bolnikih z lezijami, ki so nagnjene h krvavitvi (zlasti gastrointestinalne in intraokularne).
E.g. ibuprofen, diclofenac and meloxicam. 
Na primer ibuprofen, diklofenak in meloksikam.
TEVA Santé SA, Rue Bellocier, 89107 Sens, France 
TEVA Santé SA, Rue Bellocier, 89107 Sens, Francija
Sore mouth (stomatitis) 
• vnetje v ustih (stomatitis),
When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring. 
Ko so klopidogrel dajali podganam v obdobju laktacije, je povzročil rahlo upočasnitev razvoja mladičev.
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery. 
Če ima bolnik predviden kirurški poseg in antitrombotični učinek začasno ni zaželen, je potrebno zdravljenje s klopidogrelom prenehati 7 dni pred kirurškim posegom.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure. 
Trombotična trombocitopenična purpura (TTP) O trombotični trombocitopenični purpuri (TTP) so po uporabi klopidogrela poročali zelo redko, včasih po kratki izpostavljenosti.
• Medicines used to break down blood clots (e.g. alteplase and streptokinase). 
• zdravila, ki razgrajujejo krvne strdke (npr. alteplaza in streptokinaza).
Do not use this medicine after the expiry date which is stated on the outer carton, bottle or blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, steklenički in pretisnem omotu.
• You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
• ste doživeli hudo obliko bolečine v prsih, znano kot “nestabilna angina” ali “miokardni infarkt” (srčni napad).
- Bottles contain 30 or 100 film-coated tablets. 
- Stekleničke vsebujejo 30 ali 100 filmsko obloženih tablet.
Analysis of total mortality as a secondary endpoint did not show any significant difference between clopidogrel (5.8%) and ASA (6.0%). 
Analiza skupne umrljivosti kot sekundarnega opazovanega dogodka ni pokazala značilne razlike med klopidogrelom (5,8 %) in acetilsalicilno kislino (6,0 %).
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction. 
V podskupini z miokardnim infarktom je večina bolnikov prejemala acetilsalicilno kislino prvih nekaj dni po akutnem miokardnem infarktu.
• You have hardening of the arteries and have recently suffered from a heart attack, a stroke or have a condition known as “peripheral arterial disease” (diseases of the blood vessels except those in the brain and heart). 
• Imate stanje otrdelih arterij in ste pred kratkim doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (obolenje krvnih žil z izjemo tistih v možganih in srcu).
Approximately 88% of patients received concomitant ASA (range of 1 to 23 mg/kg/day). 
Približno 88 % bolnikov je sočasno prejemalo acetilsalicilno kislino (v razponu od 1 do 23 mg/kg/dan).
Prevention of atherothrombotic events Clopidogrel is indicated in: 
Preprečevanje aterotrombotičnih dogodkov: Klopidogrel je indiciran pri:
In addition to clinical studies experience, adverse reactions have been spontaneously reported. 
Poleg neželenih učinkov v kliničnih študijah so bile neželene reakcije prijavljene tudi spontano.
It is unknown whether clopidogrel is excreted in human breast milk. 
Ni znano ali se klopidogrel pri človeku izloča v materino mleko.
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below. 
Neželene reakcije, ki so se pojavile v kliničnih študijah ali o katerih so poročali spontano, so naštete v spodnji razpredelnici.
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet 
V študiji relativne biološke uporabnosti pri odraslih je imela pripravljena raztopina klopidogrela podoben obseg in rahlo večjo hitrost absorpcije glavnega krožečega (neaktivnega) presnovka kakor odobrena tableta.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group]. 
Ta korist se je pokazala v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom, in 363 (5,8 %) v skupini s placebom].
Therapeutic experience with clopidogrel is limited in patients with renal impairment. 
Terapevtske izkušnje s klopidogrelom so pri bolnikih z ledvično okvaro omejene.
If you take more Clopidogrel Teva Pharma B.V. than you should If you (or someone else) swallow a lot of the tablets all together, or if you think a child has swallowed any of the tablets, contact your nearest hospital casualty department or your doctor immediately. 
Če ste vzeli večji odmerek zdravila Klopidogrel Teva Pharma B.V., kot bi smeli Če vi (ali kdorkoli drug) meni, da ste pomotoma vzeli preveliko število tablet ali mislite, da jih je pogoltnil otrok, nemudoma obiščite najbližji oddelek nujne medicinske pomoči ali o tem nemudoma obvestite svojega zdravnika.
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions. 
Sočasno zdravljenje z drugimi zdravili: Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Zaradi tveganja za pojav krvavitev in hematoloških neželenih učinkov je potrebno takoj preučiti potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadar se v obdobju zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8).
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04. 
Farmakoterapevtska skupina: Zaviralci agregacije trombocitov brez heparina Oznaka ATC: B01AC04
• Heparin (medicine used to prevent blood clotting). 
• heparin (zdravilo, ki se uporablja za preprečevanje strjevanja krvi).
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below. 
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY, COMMIT in ACTIVE-A, so predstavljeni spodaj.
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake. 
Vseeno sočasna uporaba 500 mg acetilsalicilne kisline dvakrat na dan en dan ni pomembno povečala podaljšanja časa krvavitve, sprožene z jemanjem klopidogrela.
During non clinical studies in rat and baboon, the most frequently observed effects were liver changes. 
V nekliničnih študijah pri podganah in pavijanih so bili najpogosteje opaženi neželeni učinki jetrne spremembe.
The recommended dose is one 75 mg tablet per day which should be swallowed with water or another liquid. 
Običajni odmerek je ena 75 mg tableta na dan, ki jo zaužijete z vodo ali drugo tekočino.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: 
Za vse morebitne informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
Do not take a double dose to make up for a forgotten tablet. 
Ne vzemite dvojnega odmerka, da bi nadomestili posamezne izpuščene odmerke.
This leaflet was last revised in: <Month YYYY> Detailed information is available on the European Medicines Agency website: http://www.ema.europa.eu. 
Navodilo je bilo nazadnje revidirano dne <mesec/LLLL> Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
• 100 tablets bottle: 100 days 
• steklenička s 100 tabletami: 100 dni
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
NSAIDs: v klinični študiji, ki je bila izvedena pri zdravih prostovoljcih, je sočasna uporaba klopidogrela in naproksena povečala prikrito izgubo krvi iz prebavil.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
PRILOGA II A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ B. POGOJI ALI ZAHTEVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. 
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišano vrednost srčnih encimov ali troponin I ali T na najmanj dvakratno zgornjo mejo normalnega.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. 
• Aktivna patološka krvavitev kot je peptična razjeda ali intrakranialna krvavitev.
Separate one individual blister cell from the rest of the strip by gently tearing along the perforations around it. 
Oddvojite posamezno enoto pretisnega omota od preostalega traku z nežnim trganjem vzdolž perforacije okoli le-te.
Confusion or hallucinations 
• zmedenost in halucinacije,
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics. 
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starih ≥ 60 let (2 % ≥ 70 let ) in 54,5 % bolnikov, ki so prejemali fibrinolitike.
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk. 
Posebne farmakokinetične študije, ki so jih opravili z radioaktivno označenim klopidogrelom, so pokazale, da se izvorna spojina ali njeni presnovki izločajo v mleko.
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits. 
Ugotovili so, da klopidogrel nima nobenega učinka na plodnost podganjih samcev in samic ter da ni teratogen pri podganah ali kuncih.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Pharma B.V. 
Če ste noseči ali sumite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel Teva Pharma B.V..
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
Ni bilo dokazov o kancerogenem učinku pri dajanju klopidogrela 78 tednov mišim in 104 tedne podganam v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat večjo izpostavljenost kot pri človeku pri prejemanju kliničnega odmerka 75 mg/dan).
For example: o If you have recently suffered from a serious injury o If you have recently undergone surgery or are due to have surgery (including dental surgery) o If you have any blood disorder which makes internal bleeding (bleeding inside your body) more likely o If you suffer from any other illness which makes internal bleeding more likely (e.g. stomach ulcers or wounds inside the eye) 
Na primer: o če ste pred kratkim utrpeli resno poškodbo, o če ste imeli pred kratkim kirurški poseg ali načrtujete kirurški poseg (vključno z zobozdravstvenimi posegi), o če imate kakršnokoli krvno motnjo, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitve v telesu), o če imate kakršnokoli bolezen, zaradi katere ste bolj nagnjeni k notranji krvavitvi (npr. želodčne razjede in poškodbe v očeh),
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation. 
Heparin: v klinični študiji, ki je bila izvedena pri zdravih osebah, uporaba klopidogrela ni pomenila spremembe odmerka heparina ali spremembe učinka heparina na koagulacijo.
Animal studies have shown excretion of clopidogrel in breast milk. 
Študije pri živalih so pokazale, da se klopidogrel izloča v mleko.
• If you are suffering from another condition which is currently causing bleeding such as a stomach ulcer or bleeding within the brain. 
• če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je želodčna razjeda ali krvavitev v možganih.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel. 
Če je potrebno takojšnje korigiranje podaljšanega časa krvavitve, lahko s transfuzijo trombocitov dosežemo nasprotni učinek klopidogrela.
• 30 tablets bottle: 30 days 
• steklenička s 30 tabletami: 30 dni
Please take this leaflet, any remaining tablets and the container with you to the hospital or doctor so that they know which tablets were consumed. 
V bolnico oziroma k zdravniku s seboj prinesite to navodilo, preostale tablete in ovojnino, da bodo vedeli katere tablete ste zaužili.
• Carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy. 
• karbamazepin ali oksakarbazepin, zdravila za zdravljenje nekaterih oblik epilepsije,
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. 
Primarni opazovani dogodki so bili navzočnost kompozita zaradi infarkta zamašene arterije na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Varnost in učinkovitost klopidogrela so ovrednotili v 5 dvojno slepih študijah, v katere je bilo vključenih več kot 88.000 bolnikov: študija CAPRIE je obsegala primerjavo klopidogrela in acetilsalicilne kisline, v študijah CURE, CLARITY, COMMIT in ACTIVE-A, pa so primerjali klopidogrel s placebom; oboje pa so bolniki dobivali v kombinaciji z acetilsalicilno kislino in drugim standardnim zdravljenjem.
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy. 
To je veljalo za vse podskupine bolnikov, opredeljene z določenimi izhodiščnimi značilnostmi in tipom fibrinolitičnega ali heparinskega zdravljenja.
• Signs of liver problems such as yellowing of the skin and whites of the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions') 
• znaki jetrnih težav, kot je porumenelost kože in očesnih beločnic (zlatenica), ki so lahko ali pa ne povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily). 
Učinkovitost klopidogrela so opazili neodvisno od odmerka acetilsalicilnske kisline (75-325 mg enkrat na dan).
Generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); breathing difficulties, swelling or inflammation of the mouth, skin allergy, blisters on the skin 
• splošne alergijske reakcije (na primer, splošni občutek toplote z nenadnim nelagodjem do nezavesti); težave pri dihanju, otekanje ali vnetje v ustih, kožne alergije, mehurji na koži,
The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA. 
Študija ACTIVE-W je pokazala, da je bilo zdravljenje z antagonisti vitamina K učinkovitejše kot zdravljenje s klopidogrelom in acetilsalicilno kislino.
• You have an irregular heartbeat, a condition called ‘atrial fibrillation', and you cannot take medicines known as ‘oral anticoagulants' (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing. 
• imate neredno bitje srca, motnjo, imenovano "atrijska fibrilacija", in ne morete prejemati zdravil, imenovanih "peroralni antikoagulanti" (antagonisti vitamina K), ki preprečujejo nastajanje novih krvnih strdkov in preprečujejo rast obstoječih krvnih strdkov.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used. 
Ta koristni učinek se je pojavljal v vseh podskupinah, ki so bile predhodno opredeljene glede na bolnikovo starost ali spol, mesto infarkta in tip uporabljenega fibrinolitika ali heparina.
Finnland ratiopharm Oy Sími: +358 20 180 5900 
Ísland ratiopharm Oy Sími: +358 20 180 5900
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolnike je treba obvestiti, da je ob jemanju klopidogrela (samega ali v kombinaciji z acetilsalicilno kislino) čas, potreben za zaustavitev krvavitve, lahko daljši kot običajno, in da morajo svojemu zdravniku poročati o kakršnikoli neobičajni krvavitvi (mesto ali trajanje).
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Teva Pharma B.V. and acetylsalicylic acid for this condition. 
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Klopidogrel Teva Pharma B.V.
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. 
V študiji CURE število velikih krvavitev s klopidogrelom in acetilsalicilno kislino ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot pet dni pred kirurškim posegom.
• Adult patients suffering from acute coronary syndrome: 
Pri bolnikih z akutnim koronarnim sindromom:
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age ≥75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease. 
V program ACTIVE so bili randomizirani bolniki, ki so imeli dokumentirano AF, tj. bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost ≥ 75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako (TIA) ali sistemski embolus (ne v osrednjem živčevju); disfunkcijo levega prekata z iztisnim deležem levega prekata (LVEF) < 45 %; ali dokumentirano bolezen perifernih žil.
• Glycoprotein IIb/IIIa inhibitors (medicines used to stop blood clotting). 
• zaviralce glikoproteina IIb/IIIb (zdravila, ki se uporabljajo za preprečevanje strjevanja krvi).